ImageneBio Taps OX40 Expert as CMO to Accelerate Atopic Dermatitis Trial
Event summary
- ImageneBio appoints Dr. Ben Porter-Brown as Chief Medical Officer, effective February 16, 2026.
- Dr. Porter-Brown brings 20+ years of experience in autoimmune and inflammatory drug development, including leadership on OX40/OX40L programs.
- He will lead the Phase 2b ADAPTIVE trial for IMG-007 in atopic dermatitis and expand international trial sites.
- Dr. Porter-Brown receives an inducement award of 137,000 shares of ImageneBio common stock.
The big picture
ImageneBio's appointment of Dr. Porter-Brown underscores its focus on advancing IMG-007, a nondepleting anti-OX40 monoclonal antibody, through late-stage clinical trials. The move comes as the OX40/OX40L inhibition mechanism gains traction in autoimmune and inflammatory disease treatment, positioning ImageneBio to compete with established players like Sanofi. The expansion of trial sites internationally signals a strategic push to gather robust efficacy data ahead of potential regulatory filings.
What we're watching
- Trial Execution
- How Dr. Porter-Brown's leadership will impact the pace and success of the Phase 2b ADAPTIVE trial.
- International Expansion
- Whether the addition of UK and European sites will accelerate patient enrollment and data collection.
- Competitive Positioning
- The pace at which ImageneBio can differentiate IMG-007 in the crowded atopic dermatitis market.
Related topics